// App-Quantinova.ai

Abstract WMP1 : Results From A Phase 2a Study Of TMS-007, An SMTP Family Anti-inflammatory Prothrombolytic, On Patients With Acute Ischemic Stroke Up To 12 Hours After Onset

Researchers

Presenter

  • Naoko Nishimura

Principal Investigators

  • Kuniyasu Niizuma

  • Michael Wald

  • Keiko Hasegawa

  • Teiji Tominaga

  • Keiji Hasumi

Medical Centers

  • Dep Neurosurg Engineering Translat Neurosci, Tohoku Univ Grad Sch Biomedical Engineering, Sendai, Japan

  • TMS Co., Ltd., Fuchu, Japan

  • TMS Co., Ltd., Fuchu, Japan

  • Biogen, Cambridge, MA

  • Tohoku Univ Graduate Sch, Sendai, Japan

Locations

  • Japan

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Central Nervous System (CNS)

  • Gastroenterology (GU)

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Genetic Disorder

Disease

  • Gastrointestinal syndrome

  • Ischemic stroke

  • Venous thrombosis

  • Stroke

Biomarkers

  • Androgen receptor

  • Collagen type IV alpha 2 chain

Drug/Treatment

  • TMS 007

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Dose Escalation

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved